CD8A and cancer: The results demonstrate that the unprecedented combination of melatonin and IDO1 inhibitors (particularly DL-1MT) improves the performance of the anti-cancer vaccine, leading to enhanced antitumor protection and activation of E7-specific CD8+ T cell response.